CSL Limited

Price Chart

Risk-Adjusted Performance

CSL Limited (CMXHF) Price Performance

CSL Limited (CMXHF) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $97.95, up 3.03% from the previous close.

Over the past year, CMXHF has traded between a low of $95.07 and a high of $176.84. The stock has lost 37.8% over this period. It is currently 44.6% below its 52-week high.

CSL Limited has a market capitalization of $49.48B, with a price-to-earnings ratio of 15.88 and a dividend yield of 2.98%.

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.